文献速递艾滋病与性传播感染

每周三日短周期依非韦伦/恩曲他滨/替诺福韦二吡呋酯疗法的七年延长研究

Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

A-TRI-WEEK试验在24周随机期后,59名(97%)参与者进入延长阶段,接受每周三日EFV/FTC/TDF方案。7年后37人(63%)无治疗失败,仅1例因意外中断治疗出现病毒学失败且无耐药突变。该方案维持了持久病毒抑制,部分减轻但未完全预防EFV/TDF/FTC相关毒性。

要点

  • 每周三日EFV/FTC/TDF方案7年无治疗失败率为63%。
  • 仅1例病毒学失败,发生于意外中断治疗后,未检出耐药突变。
  • 停药多因中枢神经系统症状和骨密度下降,且多发生在第4-7年。

核心结论

  • 每周三日EFV/FTC/TDF方案可维持长期病毒抑制,部分减轻但未完全预防药物毒性。

研究设计与样本

  • A-TRI-WEEK试验延长研究:24周随机期后,61名完成者中59名(97%)进入延长阶段,接受每周三日EFV/FTC/TDF治疗,随访至7年。
  • 每6个月评估HIV-RNA、CD4/CD8细胞、血液尿液生化及骨密度。
  • 治疗失败预设定义为病毒学失败(HIV RNA>1000 copies/mL一次或≥50 copies/mL确认)、停药或失访。

主要发现

  • 7年后37名(63%)无治疗失败。
  • 仅1例病毒学失败,发生在意外中断治疗后,未检测到耐药突变。
  • 其他失败原因包括停药(中枢神经系统症状7例、骨密度下降7例、药物相互作用2例、方案偏好2例、癌症1例、无关死亡1例)和失访1例。
  • 实验室指标呈双相模式:初期稳定,后期eGFR和骨密度轻度下降,甘油三酯和蛋白尿升高。
  • 多数停药发生在随访后半段(第4-7年)。

关键数值与推荐

  • 病毒学失败定义:HIV RNA>1000 copies/mL一次或≥50 copies/mL确认。
  • 7年无治疗失败率为63%(37/59)。

临床怎么用

  • 该方案可作为减少药物暴露的抗逆转录病毒治疗策略,但需监测骨密度、肾功能和血脂。
  • 鉴于毒性导致的停药多发生在后期,长期随访监测至关重要。
  • 研究结果支持在现代整合酶抑制剂方案中评估类似减量策略。

局限性

  • 样本量小(59例进入延长阶段),可能限制统计效能和普遍性。
  • 单臂延长研究,无同期对照。
  • 随访中停药和失访可能影响结果解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Following a successful pilot study of a three-day-per-week regimen of efavirenz, emtricitabine, and tenofovir disoproxil fumarate, we hypothesized that this strategy would sustain virological efficacy and reduce long-term toxicities. METHODS: After a 24-week randomized phase, participants in the A-TRI-WEEK trial (ClinicalTrials.gov NCT01778413) were offered the three-day-per-week regimen. The extension was approved by the Institutional Review Board, and participants provided informed consent; follow-up continued until further participation no longer offered additional clinical or research value. HIV-RNA, CD4 and CD8 cells, blood and urine chemistries, and bone mineral density (BMD) were assessed every 6 months. Treatment failure was defined a priori as virological failure (HIV RNA >1000 copies/mL once or ≥50 copies/mL confirmed), discontinuation, or loss to follow-up. Secondary outcomes included changes in lipids, estimated glomerular filtration rate (eGFR), urine protein/creatinine, and BMD. RESULTS: Of 61 participants completing the 24-week phase, 59 (97%) entered the extension. After 7 years, 37 (63%) remained free of treatment failure. Only one participant experienced virological failure, following an unintentional treatment interruption, with no resistance mutations detected. All other failures were due to discontinuations (CNS symptoms, n = 7; BMD decline, n = 7; drug interactions, n = 2; regimen preference, n = 2; cancer, n = 1; death unrelated, n = 1; loss to follow-up, n = 1). Laboratory parameters showed biphasic patterns, with initial stability followed by modest late declines in eGFR and BMD and increases in triglycerides and proteinuria. Most discontinuations occurred in the latter half of follow-up (years 4-7). CONCLUSIONS: A three-day-per-week regimen of efavirenz, emtricitabine, and tenofovir disoproxil fumarate maintained durable long-term viral suppression, while mitigating but not fully preventing toxicities associated with EFV/TDF/FTC. These findings support reduced-exposure antiretroviral therapy and warrant evaluation of similar strategies with modern integrase inhibitor-based regimens.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Borjabad B, Rojas J, Inciarte A, et al. Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study. J Antimicrob Chemother. 2026. PMID: 41676981. doi:10.1093/jac/dkag040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。